^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HLA-A*02 + MAGEA10 expression

    i
    Other names: HLA-A, Major Histocompatibility Complex, Class I, A, HLA Class I Histocompatibility Antigen, A Alpha Chain, HLAA, HLA Class I Histocompatibility Antigen, A-1 Alpha Chain, MHC Class I Antigen HLA-A Heavy Chain, Leukocyte Antigen Class I-A, Human Leukocyte Antigen A, MAGEA10, MAGE Family Member A10, Melanoma-Associated Antigen 10, MAGE-10 Antigen, MAGE10, Cancer/Testis Antigen Family 1, Member 10, Melanoma Antigen Family A10, Cancer/Testis Antigen 1.10, MGC10599, Melanoma Antigen Family A, 10
    Entrez ID:
    3105; 4109
    Related biomarkers:
    Expression
    Mutation
    Others
    over2years
    Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10 advanced non-small cell lung cancer. (PubMed, J Immunother Cancer)
    ADP-A2M10 demonstrated an acceptable safety profile and no evidence of toxicity related to off-target binding or alloreactivity. There was persistence of ADP-A2M10 in peripheral blood as well as ADP-A2M10 trafficking into the tumor. Given the discovery that MAGE-A10 and MAGE-A4 expression frequently overlap, this clinical program closed as trials with SPEAR T cells targeting MAGE-A4 are ongoing.
    P1 data • Clinical Trial,Phase I • Journal • IO biomarker
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
    |
    HLA-A*02 • HLA-A*02 + MAGEA10 expression • HLA-A2 positive • MAGEA4 expression
    |
    cyclophosphamide • fludarabine IV • ADP-A2M10